Publication-only abstracts (abstract number preceded = by an=20 "e"), published in conjunction with the 2015 ASCO Annual Meeting but = not=20 presented at the Meeting, can be found online = only.
Approach to Serial Liquid Biopsy: Enrichment of circulating tumor = cells=20 (CTC) in breast cancer patients for cancer panel analysis.
Sub-category:
Circul=
ating=20
Tumor Cells
Category:
Tumor Biology
Meeting:
2015=20
ASCO Annual Meeting
Abstract No:
e22029
Citation:
J Clin Oncol 33, 2015 =
(suppl;=20
abstr e22029)
Author(s): = Myoung Shin=20 Kim, Sung Ho Choi, Ga-Yun Kim, Sei-Hyun Ahn, Byung Ho Sohn, Jong Won = Lee, Jong=20 Han Yu, Nak-Jung Kwon, Woo Chung Lee, Kap-Seok Yang, Beom Seok Ko, Hee = Jeong=20 Kim, Jisun Kim, Cham Han Lee, Soo Jeong Lee, Mi So Choi, Dong-Hyoung = Lee, Du=20 Yeol Han, Jinseon Lee, Byung Hee Jeon; CytoGen Inc, Seoul, South Korea; = Cytogen, Seoul, South Korea; University of Ulsan College of Medicine, = Seoul,=20 South Korea; Department of Surgery, Asan Medical Center, University of = Ulsan=20 College of Medicine, Seoul, South Korea; University of Ulsan, Asan = Medical=20 Center, Seoul, South Korea; Department of Surgery, University of Ulsan, = College=20 of Medicine, Asan Medical Center, Seoul, South Korea; Macrogen Inc., = Seoul,=20 South Korea; Industry, Seoul, South Korea
Background: Although many effective therapies improve the = survival=20 rate in breast cancer patients, a significant number of patients could = not=20 avoid recurrence and metastasis. Liquid biopsy using circulating tumor = cells=20 (CTC) is a non-invasive method to obtain tumor cells, and can be a = substitute=20 for tumor tissue biopsy. This new approach may provide molecular = profiling of=20 tumor, which can be useful for determination of personalized cancer = therapy=20 according to the molecular profiling of individual patient during the = process=20 of tumor diagnosis, recurrence, and metastasis. Methods: = Blood=20 samples (10 ml) were collected, and processed through Cytogen = protocol=20 to enrich CTCs. In brief, whole blood was incubated with specific = antibodies=20 against RBC and WBC, and spun down followed passing through micro = fabricated=20 porous filter (CytoGen). Enriched CTCs were divided into two parts, one = for=20 counting and one for molecular analysis. For CTC counting, cells were = stained=20 for EpCAM, CD45, and DAPI. DNAs were extracted, amplified and analyzed = using=20 Ion AmpliSeq Cancer Hot Spot Panel V2 (Life Technologies, NY) and PGM = 200 Seq=20 316 V2 chip (Life Technologies). MCF7 cell line was included as a = positive=20 control. Results: The average purity of enriched CTCs was = 17.7%=20 (0~100%), and the average amount of amplified DNA was 28.7 =CE=BCg = (4.8~37.8 =CE=BCg).=20 Reference location coverages were above 98.8% (98.8~99.4%) in all 11 = samples,=20 and total 30 COSMIC (catalogue of somatic mutation in cancer) were = detected in=20 10 cases. Two COSMIC (COSM 14253, COSM 33733) were detected in a = patient=20 without EpCAM positive cells, which suggesting EpCAM negative CTCs. = Highest=20 number of mutations in one patient is 7, most abundant mutations were = STK11 (3=20 cases, COSM21378, COSM25851, COSM21360), IDH2 (3 cases, COSM33733), = TP53 (2=20 cases, COSM 43753, COSM 44547), PTEN (2 cases, COSM 23626, COSM 4994, = COSM=20 4990). PTEN showed high frequency of mutations in different regions in = same=20 gene, 3 different mutations in 2 patients. Conclusions: We = provide a=20 new approach to obtain enough amounts of CTCs, which can be used for = molecular=20 analysis. And this new approach can be an applicable tool of serial = liquid=20 biopsy in breast cancer treatment.
Meeting: 2015 =
ASCO Annual =20
Meeting Abstract No: 108 First Author: Jean-Yves =
=20
Pierga | |
Meeting: 2015 =
ASCO Annual =20
Meeting Abstract No: 11003 First Author: Amelie =
=20
Schramm | |
Meeting: 2015 =
ASCO Annual =20
Meeting Abstract No: 11018 First Author: Yan =
=20
Ning | |